BridgeBio Pharma (BBIO) director granted RSUs and stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma director James C. Momtazee reported new equity awards and an ownership reclassification. He received 3,990 restricted stock units that each convert into one share of common stock and vest in full on June 22, 2027, if he continues serving on the board.

He was also granted a stock option for 5,277 shares of common stock at an exercise price of $68.92 per share, vesting in full on June 22, 2027. After these awards, he holds 19,070 shares directly, while 80,000 shares are now reported as indirectly owned through the James C. Momtazee Revocable Trust, which were previously reported as directly owned.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider MOMTAZEE JAMES C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	--
Grant/Award	Common Stock	3,990	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 shares (Direct, null); Common Stock — 19,070 shares (Direct, null); Common Stock — 80,000 shares (Indirect, By The James Momtazee Revocable Trust)

Footnotes (1)

Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSU grant: 3,990 units Direct common shares after award: 19,070 shares Indirect trust holdings: 80,000 shares +4 more

7 metrics

RSU grant 3,990 units Restricted stock units vesting June 22, 2027

Direct common shares after award 19,070 shares Direct ownership following RSU grant

Indirect trust holdings 80,000 shares Indirectly owned via James C. Momtazee Revocable Trust

Stock option size 5,277 shares Underlying common shares for new option grant

Option exercise price $68.92 per share Strike price of stock option granted June 22, 2026

Option expiration June 21, 2036 Expiration date if option is not exercised

RSU vesting date June 22, 2027 Full vesting date for the 3,990 RSUs

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), Revocable Trust, vest in full, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Revocable Trust financial

"indirectly owned through the James C. Momtazee Revocable Trust (the "Trust")..."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

vest in full financial

"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service..."

Stock Option and Incentive Plan financial

"under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 06:06 PM Accepted by SEC EDGAR 06/24/2026 - 06:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOMTAZEE JAMES C

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		A⁽¹⁾		3,990	A	$0⁽²⁾	19,070⁽³⁾	D
Common Stock								80,000⁽³⁾	I	By The James Momtazee Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		⁽⁴⁾	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person.

4. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BridgeBio Pharma (BBIO) disclose for James C. Momtazee?

BridgeBio Pharma disclosed that director James C. Momtazee received 3,990 restricted stock units and a stock option for 5,277 shares at $68.92. He also reclassified 80,000 shares from direct ownership to indirect ownership through his revocable trust.

How many BridgeBio Pharma (BBIO) shares does James C. Momtazee hold after this Form 4?

After these transactions, James C. Momtazee holds 19,070 BridgeBio Pharma common shares directly and 80,000 shares indirectly through the James C. Momtazee Revocable Trust. He also holds a stock option covering 5,277 additional shares, subject to future vesting conditions.

What are the terms of James C. Momtazee’s RSU grant from BridgeBio Pharma (BBIO)?

James C. Momtazee received 3,990 restricted stock units under BridgeBio’s 2021 Amended and Restated Stock Option and Incentive Plan. Each RSU represents one share of common stock and vests in full on June 22, 2027, contingent on his continued service on the board.

What are the details of the stock option granted to James C. Momtazee by BridgeBio Pharma (BBIO)?

James C. Momtazee was granted a stock option covering 5,277 shares of BridgeBio common stock at an exercise price of $68.92. The option vests in full on June 22, 2027, subject to his continued board service, and expires on June 21, 2036 if not exercised.

What changed about James C. Momtazee’s 80,000 BridgeBio Pharma (BBIO) shares?

The filing states that 80,000 BridgeBio Pharma shares are now reported as indirectly owned through the James C. Momtazee Revocable Trust. These shares were previously reported as directly owned by him, reflecting an ownership classification change rather than a new market transaction.